14:34 GMT31 October 2020
Listen Live
    Get short URL

    WASHINGTON (Sputnik) - US pharmaceutical and medical device company Johnson and Johnson is reported to have developed a vaccine that, in early trials, shows a strong immune response to the novel coronavirus in a single dose, an interim report published on the medical website medRxiv has revealed.

    "The safety profile and immunogenicity after only a single dose are supportive for further clinical development of [vaccine] Ad26.COV2.S at a dose level of 5x1010 vp, as a potentially protective vaccine against COVID-19," the report said on Friday. "A single dose of Ad26.COV2.S elicited strong humoral responses in the vast majority of vaccine recipients."

    The Johnson and Johnson vaccine is the fourth in the United States to enter a final phase of clinical trials.

    US President Donald Trump has promised that 100 million doses of a vaccine will be distributed throughout the United States by the end of the year. Trump earlier claimed that a vaccine could be available for distribution in the US before the 3 November presidential election.

    Many Democrats have accused Trump of trying to fast-track the vaccine approval process, sidestepping scientifically approved methods, in order to get one delivered ahead of the election.


    Production of Second Batch of Russian Sputnik V Vaccine for Public Use Underway
    COVID-19 Vaccine Likely Available for Public Use in November, Top Chinese Scientist Says
    US National Institutes of Health 'Very Concerned' With AstraZeneca's Vaccine Test Hiccup, Media Says
    US Government Releases Plan to Distribute Free COVID-19 Vaccines to All Americans
    AstraZeneca Vaccine Trial Still on Hold in US Amid Reports of 2nd Neurological Disease Case
    clinical tests, trials, Vaccine, coronavirus, COVID-19, United States
    Community standardsDiscussion